AstraZeneca completed the acquisition of our tenant SixPeaks Bio AG (Basel) on 22 October 2025, with total consideration of up to USD 300 million (incl. upfront, deferred payment, and regulatory milestones).
Next-generation obesity company with potential best- and first-in-class assets launched by Versant Ventures–
Emerges from stealth with $30 million in Series A financing and a strategic collaboration with AstraZeneca providing up to $80 million
| Building | B |
|---|---|
| Industry | Biotech |
| Employees | 22 |
| Founding year | 2022 |
Home 
About us 
Offer 
Companies 
News 
Financial support for start-ups in Basel 
Media 
Contact